{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:09:21Z","timestamp":1787317761659,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circulating cell-free DNA (ccfDNA) allows for noninvasive peripheral blood sampling of cancer-associated mutations and has established clinical utility in several solid tumors. We performed targeted next-generation sequencing of ccfDNA and bone marrow at the time of diagnosis and after achieving remission in 22 patients with acute myeloid leukemia (AML). Among 28 genes sequenced by both platforms, a total of 39 unique somatic mutations were detected. Five mutations (13%) were detected only in ccfDNA, and 15 (38%) were detected only in bone marrow. Among the 19 mutations detected in both sources, the concordance of variant allelic frequency (VAF) assessment by both methods was high (R2 = 0.849). Mutations detected in only 1 source generally had lower VAF than those detected in both sources, suggesting that either method may miss small subclonal populations. In 3 patients, sequencing of ccfDNA detected new or persistent leukemia-associated mutations during remission that appeared to herald overt relapse. Overall, this study demonstrates that sequencing of ccfDNA in patients with AML can identify clinically relevant mutations not detected in the bone marrow and may play a role in the assessment of measurable residual disease. However, mutations were missed by both ccfDNA and bone marrow analyses, particularly when the VAF was &amp;lt;10%, suggesting that ccfDNA and bone marrow may be complementary in the assessment and monitoring of patients with AML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001156","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T11:38:34Z","timestamp":1587641914000},"page":"1670-1677","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"first","affiliation":[{"name":"Genomic Testing Cooperative, Irvine, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Franquiz","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Assi","sequence":"first","affiliation":[{"name":"Lebanese American University Medical Center\u2013Rizk Hospital, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Matthews","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Ma","sequence":"first","affiliation":[{"name":"Genomic Testing Cooperative, Irvine, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Kornblau","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-3613","authenticated-orcid":false,"given":"Zeev","family":"Estrov","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"issue":"10147","key":"2020042811283505700_B1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"2020042811283505700_B2","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2020042811283505700_B3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"2020042811283505700_B4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"13","key":"2020042811283505700_B5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"2020042811283505700_B6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020042811283505700_B7","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","article-title":"How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?","volume":"104","author":"Short","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2020042811283505700_B8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.10432","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow","volume":"92","author":"Maurillo","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2020042811283505700_B9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2020042811283505700_B10","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.3324\/haematol.2016.159988","article-title":"BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors","volume":"102","author":"Byun","year":"2017","journal-title":"Haematologica"},{"issue":"26","key":"2020042811283505700_B11","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.05.9493","article-title":"Prediction of breast tumor progression by integrity of free circulating DNA in serum","volume":"24","author":"Umetani","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020042811283505700_B12","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC\u2013challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"25","key":"2020042811283505700_B13","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020042811283505700_B14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3324\/haematol.2013.093765","article-title":"Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring","volume":"99","author":"Luthra","year":"2014","journal-title":"Haematologica"},{"issue":"22","key":"2020042811283505700_B15","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1002\/cncr.30883","article-title":"A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"2020042811283505700_B16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"2020042811283505700_B17","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020042811283505700_B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.leu.2401951","article-title":"Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1\/ETO fusion transcript found only by PCR testing","volume":"15","author":"Sarriera","year":"2001","journal-title":"Leukemia"},{"issue":"4","key":"2020042811283505700_B19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020042811283505700_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","author":"Stetson","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"2020042811283505700_B21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020042811283505700_B22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2020042811283505700_B23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"7","key":"2020042811283505700_B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/gtmb.2015.0278","article-title":"Deep sequencing of cell-free peripheral blood DNA as a reliable method for confirming the diagnosis of myelodysplastic syndrome","volume":"20","author":"Albitar","year":"2016","journal-title":"Genet Test Mol Biomarkers"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1670\/1725408\/advancesadv2019001156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/8\/1670\/1725408\/advancesadv2019001156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T11:54:10Z","timestamp":1722772450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/8\/1670\/454447\/Targeted-nextgeneration-sequencing-of-circulating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001156","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]}}}